iShares Biotechnology ETF
IBB
IBB
522 hedge funds and large institutions have $4.15B invested in iShares Biotechnology ETF in 2016 Q4 according to their latest regulatory filings, with 127 funds opening new positions, 172 increasing their positions, 148 reducing their positions, and 60 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
522
Holders Change
+59
Holders Change %
+12.74%
% of All Funds
13.07%
Holding in Top 10
21
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-16%
% of All Funds
0.53%
New
127
Increased
172
Reduced
148
Closed
60
Calls
$641M
Puts
$990M
Net Calls
-$349M
Net Calls Change
+$237M
Top Buyers
| 1 |
Jane Street
New York
|
$47.9M |
| 2 |
Morgan Stanley
New York
|
$405M |
| 3 |
UBS Group
Zurich,
Switzerland
|
$176M |
| 4 |
N
Natixis
Paris,
France
|
$39.9M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
$91.5M |
Top Sellers
| 1 |
Citigroup
New York
|
$328M |
| 2 |
Goldman Sachs
New York
|
$272M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
$70.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
$501M |
| 5 |
SG Americas Securities
New York
|
$3.96M |
